The Medical Group Management Association (MGMA) has submitted comments to the U.S. Department of Health and Human Services (HHS) in response to its request for information on accelerating the adoption of AI in clinical care.
"Federal AI policies should establish expectations that ensure AI tools are safe, interoperable, transparently developed, and usable within a clinician's workflow for their direct review and involvement, without exacerbating administrative burden," the MGMA said in a statement.
The HHS requested information on how the agency can accelerate the adoption of AI in the clinical care space in December 2025. The MGMA called on HHS to ensure sustainable reimbursement pathways and clear standards that support responsible AI adoption, particularly for smaller and independent practices, for which infrastructure readiness and cost shape adoption decisions.
Among its specific recommendations, the MGMA said AI should augment rather than replace clinical judgment, that transparency is foundational to trust and adoption, that workflow integration is critical beyond technical performance, that oversight should match risk level, and that policies should not shift liability onto medical groups for technology developed outside the practice.
"We are committed to working in partnership with HHS to ensure medical groups are empowered and enabled through clear and proportionate guardrails," the MGMA said.
